JP2024533067A - 抗ｂｔｎ３ａ治療に対するレスポンダーの選択 - Google Patents

抗ｂｔｎ３ａ治療に対するレスポンダーの選択 Download PDF

Info

Publication number
JP2024533067A
JP2024533067A JP2024512096A JP2024512096A JP2024533067A JP 2024533067 A JP2024533067 A JP 2024533067A JP 2024512096 A JP2024512096 A JP 2024512096A JP 2024512096 A JP2024512096 A JP 2024512096A JP 2024533067 A JP2024533067 A JP 2024533067A
Authority
JP
Japan
Prior art keywords
antibody
btn3a
cells
seq
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024512096A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023041622A5 (https=
JP2024533067A5 (https=
Inventor
エマニュエル バレンティン，
ポール フローナ，
ガサート， オード デ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imcheck Therapeutics SAS
Original Assignee
Imcheck Therapeutics SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcheck Therapeutics SAS filed Critical Imcheck Therapeutics SAS
Publication of JP2024533067A publication Critical patent/JP2024533067A/ja
Publication of JPWO2023041622A5 publication Critical patent/JPWO2023041622A5/ja
Publication of JP2024533067A5 publication Critical patent/JP2024533067A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2024512096A 2021-09-15 2022-09-15 抗ｂｔｎ３ａ治療に対するレスポンダーの選択 Pending JP2024533067A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21306272 2021-09-15
EP21306272.2 2021-09-15
PCT/EP2022/075608 WO2023041622A1 (en) 2021-09-15 2022-09-15 Selection of responders for anti-btn3a treatment

Publications (3)

Publication Number Publication Date
JP2024533067A true JP2024533067A (ja) 2024-09-12
JPWO2023041622A5 JPWO2023041622A5 (https=) 2025-09-24
JP2024533067A5 JP2024533067A5 (https=) 2025-09-24

Family

ID=77998935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024512096A Pending JP2024533067A (ja) 2021-09-15 2022-09-15 抗ｂｔｎ３ａ治療に対するレスポンダーの選択

Country Status (6)

Country Link
US (1) US20230227558A1 (https=)
EP (1) EP4401837A1 (https=)
JP (1) JP2024533067A (https=)
CN (1) CN118475611A (https=)
TW (1) TW202313695A (https=)
WO (1) WO2023041622A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20260034T1 (hr) * 2018-08-01 2026-02-27 Imcheck Therapeutics Anti-btn3a antitijela i njihova upotreba u liječenju raka ili infektivnih poremećaja
JP2026506893A (ja) * 2023-02-23 2026-02-27 イムチェック セラピューティクス エスエーエス Ｂｔｎ３ａ活性化抗体と免役チェックポイント阻害剤の併用
TW202506731A (zh) * 2023-04-27 2025-02-16 法商感應檢查療法公司 治療多重抗藥性細菌感染之方法
WO2024251981A1 (en) * 2023-06-09 2024-12-12 Umc Utrecht Holding B.V. Detecting and/or modulating susceptibility to btn2a1 and/or btn3a1 targeting therapeutics
WO2024261239A1 (en) * 2023-06-23 2024-12-26 Imcheck Therapeutics Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
HRP20260034T1 (hr) 2018-08-01 2026-02-27 Imcheck Therapeutics Anti-btn3a antitijela i njihova upotreba u liječenju raka ili infektivnih poremećaja

Also Published As

Publication number Publication date
EP4401837A1 (en) 2024-07-24
US20230227558A1 (en) 2023-07-20
TW202313695A (zh) 2023-04-01
WO2023041622A1 (en) 2023-03-23
CN118475611A (zh) 2024-08-09

Similar Documents

Publication Publication Date Title
US20240002515A1 (en) Methods and antibodies for modulation of immunoresponse
JP6650537B2 (ja) 抗ｃｔｌａ−４抗体
JP6839761B2 (ja) 抗ＰＤ−Ｌ１抗体との組み合わせのための抗Ｔｉｍ−３抗体
US20230227558A1 (en) Selection of responders for anti-btn3a treatment
JP2022065073A (ja) Ｂｃｍａ結合分子及びその使用方法
CN107530428B (zh) Icos的抗体
JP2019517773A (ja) 抗ｌａｇ−３抗体
JP2020514363A (ja) 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５
JP2021511818A (ja) Ｖｉｓｔａ抗原結合性分子
CN120554507A (zh) 拮抗剂抗cd7抗体
JP2018525367A (ja) がんの治療における抗ｐｄ−１抗体および抗ｍ−ｃｓｆ抗体の併用
JP2020520912A (ja) 抗ｇｉｔｒアゴニスト抗体での癌の処置
KR20220035150A (ko) 특정 환자에서 암의 치료를 위한 항체 조합물
KR20190130506A (ko) 골수유래억제세포 관련 질환의 예방 및 치료 용도
CN119384293A (zh) 使用vista抗原结合分子治疗和预防癌症
WO2023052541A1 (en) Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
JP7660823B2 (ja) 抗ｐｄ－１ポリペプチド及びその使用
JP2026506893A (ja) Ｂｔｎ３ａ活性化抗体と免役チェックポイント阻害剤の併用
US20240084014A1 (en) Multispecific binding compounds that bind to pd-l1
AU2022377628A1 (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
EP4103611A1 (en) Bispecific antibodies binding hvem and cd9
HK1248127B (en) Antibodies to icos
HK40000388A (en) Anti-ctla-4 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250912